Richard B. Gaynor, MD
President of Research & Development
Dr. Richard Gaynor started serving as President of Research and Development of Neon Therapeutics in 2016, after being the Senior Vice President of global product development and medical affairs since 2013 at Lilly Oncology. At Lilly Oncology, he led preclinical and early clinical research and directed the biomarker and research group.
Dr. Gaynor received his doctor of medicine degree from the University Of Texas Southwestern Medical School. He served his internship and residency in internal medicine at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on the faculty there. He received board certification in internal medicine, hematology and medical oncology.
Prior to joining Lilly, Gaynor was a professor of medicine and microbiology at the University of Texas Southwestern Medical Center (UTSW) in Dallas and held several important leadership positions. He was chief of the Division of Hematology and Oncology at UTSW and director of the Harold C. Simmons Comprehensive Cancer Center there in addition to his work as the Lisa K. Simmons distinguished chair in comprehensive oncology. He served on numerous NIH advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.
Gaynor is on the editorial board of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He serves on the board of the Damon Runyon Cancer Research Foundation and the Walther Cancer Institute and on several committees for the American Association of Cancer Research and other leading cancer organizations.